2.2. Which criteria for the anatomopathological diagnosis of malignant pleural mesothelioma?;2.2. Quels critères pour le diagnostic anatomopathologique du mésothéliome pleural malin?

Revue des Maladies Respiratoires

Volumn 23, Issue 4 C3, 2006, Pages

  Galateau Salle F ^a   Copin, M C ^b   Delajartre, A Y ^c   Vignaud, J M ^d   Astoul, P ^e   Pairon, J C ^f   Le Pimpec Barthes, F ^g   Brochard, P ^h  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

^e HÔPITAL SAINTE MARGUERITE   (France)

^f CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER SURGERY; CLINICAL FEATURE; HUMAN; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; NOTE; PLEURA BIOPSY; PLEURA MESOTHELIOMA; THORACOSCOPY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; MESOTHELIOMA; PATHOLOGY; PLEURA TUMOR;

HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 33847012561     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0761-8425(06)71783-1     Document Type: Note

References (84)

1. Browne K, Smither WJ : Asbestos-related mesothelioma: factors discriminating between pleural and peritoneal sites. Br J Ind Med 1983 ; 40 : 145-52.
2. Goldberg M, Imbernon E, Rolland P, Gilg Soit Ilg A, Savès M, de Quillacq A et coll. : The French National Mesothelioma Surveillance Program. OEM 2006 published on line first, Feb 9.
3. Coggon D, Inskip H, Winter P, Pannett B : Differences in occupational mortality from pleural cancer, peritoneal cancer and asbestosis. Occup Environ Med 1995 ; 52 : 775-7.
4. nd edition, 2004.
5. Roggli VL, Sharma A, Butnor KJ, Vollmer RT : Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. Ultrastruct Pathol 2002 ; 26 : 55-65.
6. nd Ed. Williams & Wilkins Baltimore. 1998.p 356.
7. re edition, 2005.
8. Sporn TA, Roggli VL : Mesothelioma. In: Pathology of asbestos associated diseases Roggli VL, Oury TD, Sporn TA eds Springer-Verlag New York second edition, 2003.
9. Boutin C, Rey F : Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: Diagnosis. Cancer 1993 ; 72 : 389-93.
10. Boutin C, Rey F, Gouvernet J, Viallat JR, Astoul P, Ledoray V : Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging. Cancer 1993 ; 72 : 394-404.
11. Allen T, Cagle PT, Churg AM, Colby TV, Gibbs AR, Hammar SP, et coll. : Localized malignant mesothelioma. Am J Surg Pathol 2005 ; 29 : 866-73.
12. Churg A : What's new in the pleura. Arch Pathol Lab Med 2005 ; 125 : 1405-6.
13. Johnson WD : The cytological diagnosis of cancer in serous effusions. Acta Cytol 1996 ; 10 : 161-2.
14. Salyer WR, Eggleston JC, Erozan YS : Efficacy of pleural needle biopsy and pleural fluid cytology in the diagnosis of malignant neoplasm involving the pleura. Chest 1975 ; 5 : 536-9.
15. Prakash UBS, Reiman HM : Comparaison of needle biopsy with cytologic analysis for the evaluation of pleural effusisons:analysis of 414 cases. Mayo Clinic Proc 1985 ; 60 : 158-64.
16. Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES : The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 1997 ; 111 : 106-9.
17. Yang GCH : Long microvilli of mesothelioma are conspicuous in pleural effusisons processed by ultrafast papanicolaou stain. Cancer 2003 ; 99 : 17-22.
18. Ylagan LR, Zai J : The value of Thinprep and cytospin preparation in pleural effusion cytological diagnosis mesothelioma and adenocarcinoma. Diagn Cytopathol 2005 ; 32 : 137-44.
19. Dejmek A, Hjerpe A : Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis. Cytopathology 2000 ; 11 : 8-17.
20. Loddenkemper R, Grosser H, Gabler A et coll. : Prospective evaluation of biopsy methods in the diagnosis of malignant pleural effusisons: intrapatient comparison between pleural fluid cytology, blind needle biopsy and thoracoscopy. Am Rev Respir Dis 1983 ; 127 : 114.
21. Kendall SW, Bryan AJ, Large SR et coll. : Pleural effusisons: is thoracoscopy a reliable investigation? A retrospective review. Respir Med 1992 ; 86 : 437-40.
22. Walzl G, Wyser C, Smedema J, et coll. : Comparing the diagnosis yield of Abrams needle pleural biopsy and thoracoscopy. Am J Respir Critic Care Med 1996 ; 153 : A 460.
23. Loddenkemper R : Thoracoscopy- State of the art. Eur Respir J 1998 ; 11 : 213-22.
24. Adams RF, Gray W, Davies RJ, Gleeson FV : Percutaneous image-guided cutting needle biopsy [CNB] of the pleura in the Dx of malignant mesothelioma. Chest 2001 ; 120 : 1798-802.
25. Blanc FX, Atassi K, Bignon J, Housset B : Diagnostic value of medical thoracoscopy in pleural disease. Chest 2002 ; 121 : 1677-83.
26. Maskell NA Gleeson FV, Davies : Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial. Lancet 2003 19 ; 361 : 1326-30.
27. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (Eds) : World Health Organization Classification of tumors. Tumors of the lung, pleura, thymus and heart. IARC (Lyon) 2004.
28. Galateau-Salle F, Brambilla E, Cagle P, Churg A, Colby T, Hammar S, et coll. : Pathology of Malignant mesothelioma ; an update of the International mesothelioma panel Eds Galateau - Sallé, 2006 Springer Verlag.
29. Henderson DW, Attwood HD, Constance TJ, Shilkin KB, Steele RH : Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma. Ultrastruct Pathol 1988 : 367-84.
30. Khalidi HS, Medeiros LJ, Battifora H : Lymphohistiocytoid mesothelioma. An often misdiagnosed variant of sarcomatoid malignant mesothelioma. Am J Clin Pathol 2000 ; 113 : 649-54.
31. Yao DX, Shia J, Erlandson RA, Klimstra DS : Lymphohistiocytoid mesothelioma: a clinical, immunohistochemical and ultrastructural study of four cases and literature review. Ultrastruct Pathol 2004 ; 28 : 213-28.
32. Ordonez NG, Mackay B : Glycogen-rich mesothelioma. Ultrastruct Pathol 1999 ; 23 : 401-6.
33. Chang HT, Yantiss RK, Nielsen GP, et coll. : Lipid-rich diffuse malignant mesothelioma: a case report. Hum Pathol 2000 ; 31 : 876-9.
34. Ordonnez NG, Mac Kay B : Clear cell mesothelioma. Ultrastruct Pathol 1999 ; 23 : 331-6.
35. Dessy E, Pietra GG : Unusual clear cell variant of epithelioid mesothelioma. Arch Pathol Lab Med 2001 ; 125 : 1588-90.
36. Shanks JH, Harris M, Banerjee SS et coll. : Mesotheliomas with deciduoid morphology: a morphologic spectrum and a variant not confined to young females. Am J Surg Pathol 2000 ; 24 : 285-94.
37. Hammar SP, Bockus DE, Remington FL et coll. : Mucin-positive epithelial mesotheliomas : a histochemical, immunohistochemical, and ultrastructural comparison with mucin-producing pulmonary adenocarcinomas. Ultrastruct Pathol 1996 ; 20 : 293-325.
38. Churg A, Colby TV, Cagle P, Corson J, Gibbs AR, Gilks B, et coll. : The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 2000 ; 24 : 1183-2000.
39. Henderson DW, Shilkin KB, Whitaker D : Reactive mesothelial hyperplasia versus mesothelioma, including mesothelioma in situ. Am J Clin Pathol 1998 ; 110 : 397-404.
40. Galateau-Salle F, Cagle P : Non malignant versus malignant proliferations on pleural biopsy. In : Diagnostic Pulmonary Pathology ed P. Cagle Marcel Dekker, Inc. New York Basel, 2000.
41. Galateau-Salle F, Vignaud JM, Burke L, Gibbs A, Brambilla R, Attanoos R, et coll. : Well- Differentiated Mesothelioma of the Pleura. Am J Surg Pathol 2004 ; 28 : 534-40.
42. Butnor KJ, Sporn TA, Hammar SP, Roggli VL : Well-differentiated papillary mesothelioma. Am J Surg Pathol 2001 ; 25 : 1304-9.
43. England DM, Hochlozer L, McCarthy MJ : Localized benign and malignant fibrous tumor of the pleura. A clinicopathologic review of 223 cases. Am J Surg Pathol 1989 ; 13 : 640-58.
44. Ordonnez NG : Localized (solitary) fibrous tumor of the pleura. Adv Anat Pathol 2000 ; 7 : 327-40.
45. Riera JR, Astengo-Osuna C, Longmate JA, Battifora H : The immunohistochemical diagnostic panel for epithelial mesothelioma: reevaluation after heat-induced epitope retrieval. Am J Surg Pathol 1997 ; 21 : 1409-19.
46. Garcia-Prats MD, Ballestin C, Sotelo T, Lopez-Encuentra A, Mayordomo JI : A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours. Histopathology 1998 ; 32 : 462-72.
47. Ordonez NG : Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol 1998 ; 22 : 1215-21.
48. Khoor A, Whitsett JA, Stahlman MT, Olson SJ, Cagle PT : Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol 1999 ; 30 : 695-700.
49. Ordonez NG : Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000 ; 24 : 598-606.
50. Comin CE, Novelli L, Boddi V, Paglierani M, Dini S : Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol 2001 ; 32 : 529-36.
51. Abutaily AS, Addis BJ, Roche WR : Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol 2002 ; 55 : 662-8.
52. Miettinen M, Sarlomo-Rikala M : Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lungcarcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol 2003 ; 27 : 150-8.
53. Ordonez NG : The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003 ; 27 : 1031-51.
54. Carella R, Deleonardi G, D'Errico A, Salerno A, Egarter-Vigl E, Seebacher C, et coll. : Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol 2001 ; 25 : 43-50.
55. Attanoos RL, Galateau-Salle F, Gibbs AR, Muller S, Ghandour F, Dojcinov SD : Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma. Histopathology 2002 ; 41 : 42-9.
56. Attanoos RL, Dojcinov SD, Webb R, Gibbs AR : Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Histopathology 2000 ; 37 : 224-31.
57. Van de Rijn M, Rouse RV : CD34; a review. Applied immunohistochemistry 1994 ; 2 : 71-80. ;
58. Moll R, Frank WW, Schiller DL, Geiger B, Kepler R : The catalog of human cytokeratins: pattern of expression in normal epithelia, tumors and cultured cells. Cell 1982 ; 31 : 11-24.
59. Chu PG, Weiss LM : Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol 2002 ; 15 : 6-10.
60. Ordonez NG : Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003 ; 16 : 192-7.
61. Amin KL, Litzzky LA, Smythe WR et coll. : Wilm's tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 1995 ; 146 : 344-56.
62. Kumar Singh S, Segers K, Rodeck U et coll. : WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growht factor receptor expression, cell type transition and prognosis. J Pathol, 1991 ; 187 : 467-71.
63. Ordonnez G, Ordonnez MD : D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignnat mesothelioma. Hum Pathol 2005 ; 35 : 372-80.
64. Ordonnez NG : Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003 ; 27 : 1418-28.
65. Kahn HJ, Bailey D, Marks A : Monoclonal antibody D2-40, a new marker o lymphatic endothelium, reacts with Kaposi 's sarcoma and a subset of angiosarcomas. Mod Pathol 2002 ; 15 : 434-40.
66. Cury PM, Butcher DN, Corrin B, Nicholson AG : The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia. J Pathol 1999 ; 189 : 251-7.
67. Attanoos RL, Griffin A, Gibbs AR : The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for etc... and comparative evaluation with epithelial membrane antigen, p53, platelet derived growth factor-receptor, p-glycoprotein and bcl-2. Histopathology, 2003 ; 43 : 231-8.
68. Ordonez NG : Mesothelioma with clear cell features: an ultrastructural and immunohistochemical study of 20 cases. Hum Pathol 2005 ; 36 : 465-73.
69. King JE, Thatcher N, Pickering CA, Hasleton P : Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology 2006 ; 48 : 223-32.
70. Kahn HJ, Bailey D, Marks A : Monoclonal antibody D2-40, a new marker o lymphatic endothelium, reacts with Kaposi 's sarcoma and a subset of angiosarcomas. Mod Pathol 2002 ; 15 : 434-40.
71. Yokokawa J, Palena C, Arlen P, Hassan R, Ho M, Pastan I, et coll. : Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res 2005 ; 11 : 6342-51.
72. Onda M, Willingham M, Nagata S, Bera TK, Beers R, Ho M, et coll. : New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clin Cancer Res 2005 ; 11 : 5840-6.
73. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, et coll. : Soluble mesothelin-related protein - a blood test for mesothelioma. Lung Cancer 2005 ; 49 : S109-11.
74. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, et coll. : Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 2005 ; 11 : 3766-72.
75. Roggli VL, Sanfilippo F, Shelburne JD : Mesothelioma in Roggli VL, Greenberg SD and Pratt PC (eds): Pathology of Asbestos-associated diseases, Boston, Little, Brown and Company, 1992, pp 109-64.
76. Hammar SP : Pleural diseases in Dail DH, Hammar SP (eds): Pulmonary Pathology (ed 2) New York, Springer,1994, pp 1487-579.
77. Ordonnez NG, Mac Kay B : The role of immunohistochemistry and electron microscopy in distinguishing epithelial mesothelioma of the pleura from adenocarcinoma. Adv Anat Pathol 1996 ; 3 : 173-93.
78. Comin CE, deKlerk NH, Henderson DW: Malignant mesothelioma: current conundrums over risk estimates and whither electron microscopy for diagnosis? Ultrastruct Pathol 1997 ; 21 : 315-20.
79. Ordonnez NG, Mac KayB : Electron microscopy in tumor diagnosis: indications for its use in the immunohistochemical era. Hum Pathol 1998 ; 29 : 1403-11.
80. Oury TD, Hammar SP, Roggli VL : Ultrastructural features of diffuse malignant mesotheliomas. Hum Pathol 1998 ; 29 : 1382-92.
81. Sakuma N, Kamei T, Ishihara T : Ultrastructure of pleural mesothelioma and pulmonary adenocarcinoma in malignant effusions as compared with reactive mesothelial cells. Acta Cytol 1999 ; 43 : 777-85.
82. Mohr S, Keith G, Galateau-Salle F, Icard P, Rhin BH : Cell protection resistance and invasiveness of two malignant mesotheliomas by 10K - microarray. Biochim Biophys Acta 2004 ; 1688 : 43-60.
83. Gordon et coll. : Validation of genomics-based prognostic tests in malignant mesothelioma. Clin Cancer Res 2005 ; 11 : 4406-14.
84. Gordon et coll. : Identification of novel candidates oncogenes and tumor suppressor genes in malignant mesotheliomas using large scale transcriptional profiling. Am J Pathol 2005 ; 166 : 1827-40.